Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Country:  U.S.A.
Trial Type:  Treatment
Treatment/Intervention:  hematopoietic stem cell transplantation
Results 1-25 of 193 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Peripheral Blood Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 70 and under
Trial IDs: MT2006-13, NCI-2010-02369, 0607M89052, UMN-MT2006-13, NCT00630565
Chemotherapy or Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1227, NCI-2013-01746, CIR00000621, NA_00071844, NA_00071844 / CR00001237, NCT01588951
Combination Chemotherapy and Total Body Irradiation in Treating Patients with Fanconi Anemia Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 17 and under
Trial IDs: MT2006-05, NCI-2017-01078, NCT00352976
Total Body Irradiation and Combination Chemotherapy before Donor Progenitor Cell Transplant in Treating Younger Patients with Hematologic Malignancies
Status: Active
Phase: Phase III
Type: Treatment
Age: 21 and under
Trial IDs: SCT 0307, NCI-2015-00131, 2007-13121, CMH SCT 0307, NCT00619879
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Double Cord Versus Haploidentical (BMT CTN 1101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 5U24CA076518, 715, NCT01597778
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 30 to 70
Trial IDs: E1910, NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01, NCT02003222
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 65
Trial IDs: BMTCTN1301, NCI-2015-01813, U01HL069294, NCT02345850
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Status: Active
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, 1407-GUCG, 2014-003930-17, PA031102_A01PAMDREVW01, NCT02375204
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: AC220-A-U302, NCI-2016-00846, NCT02668653
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Active
Phase: Phase III
Type: Treatment
Age: 55 and over
Trial IDs: Iomab-01, NCI-2016-01853, NCT02665065
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 2 to 21
Trial IDs: AALL1631, NCI-2016-01588, NCT03007147
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703, NCT02085408
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 17 to 70
Trial IDs: 2067.00, NCI-2011-01352, FHCRC-2067.00, 6364, NCT00622895
Combination Chemotherapy and Stem Cell Transplantation in Treating Patients with Fanconi Anemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Under 60
Trial IDs: MT2000-09, NCI-2017-01075, UMN-MT2000-09, UMN-2007BMT031, NCT00630253
Fludarabine Phosphate, Busulfan, Anti-thymocyte Globulin, and Total-Body Irradiation before Donor Stem Cell Transplant in Treating Younger Patients with Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: SCT 0208, NCI-2015-00140, CMH SCT 0208, NCT00679536
Lenalidomide, High-Dose Melphalan, and Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0290, NCI-2010-01423, NCT01142232
Bendamustine Hydrochloride, Ofatumumab, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11D.404, NCI-2011-03434, 152, 2011-61, NCT01458366
Start Over